Takeda Pharmaceutical Appoints Julie Kim as CEO Following 18-Month Transition
Takeda Pharmaceutical appointed Julie Kim as Representative Director, President and Chief Executive Officer at its 150th Annual General Meeting of Shareholders, completing an 18-month leadership transition [1]. Shareholders elected Kim as a new internal director to the Board of Directors on June 24, 2026, and the Board subsequently appointed her to the chief executive role [1].
Takeda Pharmaceutical appointed Julie Kim as Representative Director, President and Chief Executive Officer at its 150th Annual General Meeting of Shareholders in Osaka, completing an 18-month CEO transition [1][2]. Shareholders elected Kim as a new internal director to the Board of Directors during the meeting held June 24, 2026 [1]. Following the vote and conclusion of the meeting, the Board appointed her to the top executive role [1].
The appointment marks the final step in a planned leadership succession at the Japanese pharmaceutical company, which trades on the Tokyo Stock Exchange under ticker 4502 and on the New York Stock Exchange as [1]. Kim transitions from her prior role within the organization to become the company's chief executive [2].
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.